Related Experiment Video

Updated: Aug 23, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Molecular Mechanisms of Castrate-Resistant Prostate Cancer

Srinath Kotamarti1, Andrew J Armstrong2, Thomas J Polascik1

  • 1Division of Urology, Duke Cancer Institute, 20 Duke Medicine Circle, Durham, NC 27710, USA.

The Urologic Clinics of North America
|October 29, 2022
PubMed

Insights

Newer castrate-resistant prostate cancer (CRPC) therapies often fail due to resistance. Understanding the molecular mechanisms driving CRPC progression, like lineage plasticity, is crucial for improving patient outcomes.

Area of Science:

  • Oncology
  • Cancer Biology
  • Genitourinary Cancers

Background:

  • Castrate-resistant prostate cancer (CRPC) presents significant therapeutic challenges.
  • Many patients do not respond to current treatments or develop secondary resistance.
  • Understanding resistance mechanisms is critical for advancing CRPC care.

Purpose of the Study:

  • To review and synthesize current knowledge on the molecular mechanisms of therapeutic resistance in CRPC.
  • To highlight the role of androgen-receptor-related pathways and alternative resistance mechanisms.
  • To emphasize the importance of understanding lineage plasticity and neuroendocrine transformation in CRPC.

Main Methods:

  • Literature review and synthesis of existing research on CRPC resistance.
  • Analysis of identified genomic alterations and molecular pathways implicated in resistance.
  • Focus on mechanisms such as lineage plasticity and neuroendocrine transformation.

Main Results:

  • Multiple androgen-receptor-related mechanisms contribute to CRPC resistance.
  • Alternative pathways, including lineage plasticity and neuroendocrine transformation, are key drivers of resistance.
  • Various genomic alterations are associated with treatment failure in CRPC.

Conclusions:

  • A deeper understanding of the molecular basis of CRPC resistance is essential.
  • Identifying resistance mechanisms can inform future therapeutic strategies and clinical decision-making.
  • Further research into lineage plasticity and genomic alterations may lead to improved treatments for advanced prostate cancer.
Keywords:
Androgen receptorCastrate resistanceProstate cancerTherapeutic resistance

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.0K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K